Full Data
?
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on the Chinese Stock Markets
Join Now!
Need this critical market data?
Access thousands of market events, data points, and news articles!
Already have an account?
Login
Home » News » Hengrui's "Double Ai" program achieved the primary study endpoint in the international phase III clinical trial